Lanreotide is a long-acting synthetic octapeptide somatostatin analogue that primarily binds to somatostatin receptor subtypes, particularly SSTR2 and SSTR5. It suppresses the secretion of several hormones, including growth hormone, and is used in the management of acromegaly and certain neuroendocrine tumors.
Lanreotide is formulated as a long-acting injectable depot preparation, providing sustained pharmacological activity.
Lanreotide is a specialized peptide pharmaceutical ingredient requiring controlled peptide synthesis, purification and comprehensive characterization.
Important quality attributes include identity, peptide purity, related peptides, water content, residual solvents, counter-ion content, molecular integrity, microbial quality and stability.
CAS Number: 108736-35-2
Molecular Formula: C54H69N11O10
Molecular Weight: 1096.20 g/mol
Drug Class: Somatostatin Analogue
Pharmacological Class: Somatostatin Receptor Agonist
Therapeutic Class: Hormonal / Antineoplastic Agent
Therapeutic Area: Endocrinology / Oncology
Lanreotide mimics the activity of endogenous somatostatin by binding to somatostatin receptors, particularly SSTR2 and SSTR5.
This receptor activation suppresses hormone secretion and can:
Lanreotide is used for:
Specific indications and dosing depend on the applicable regulatory labeling.
Lanreotide is structurally related to somatostatin but has been modified to provide greater metabolic stability and prolonged activity.
Its long-acting formulation allows administration at relatively extended intervals compared with naturally occurring somatostatin.
Typical peptide API manufacturing may involve:
Lanreotide API quality evaluation may include:
Lanreotide should be stored according to validated stability data and approved product requirements. Appropriate temperature control and protection from moisture, excessive heat and inappropriate light exposure should be maintained.
Lanreotide is relevant to research involving:
Lanreotide is a long-acting synthetic somatostatin analogue with CAS Number 108736-35-2, molecular formula C54H69N11O10, and molecular weight 1096.20 g/mol. It primarily activates somatostatin receptors SSTR2 and SSTR5 and is used in the treatment of acromegaly and certain neuroendocrine tumors.
| Parameter | Specification |
|---|---|
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |